Getting a medical device to market in the United States requires FDA clearance or approval through one of three main regulatory pathways, each with different levels of evidence, cost, and time. The path your device takes depends almost entirely on its risk classification. Understanding that classification is the first real decision point, and everything else flows from it.
How the FDA Classifies Medical Devices
The FDA uses a risk-based system with three classes. Class I covers the lowest-risk devices, things like bandages, tongue depressors, and handheld surgical instruments. Class II includes moderate-risk devices like powered wheelchairs, pregnancy tests, and infusion pumps. Class III is reserved for the highest-risk devices: those that sustain life, are implanted in the body, or present a potential unreasonable risk of illness or injury. Pacemakers, heart valves, and implantable defibrillators fall here.
All three classes are subject to what the FDA calls “general controls,” which include requirements around registration, labeling, and reporting. Class II devices also require “special controls,” such as specific performance standards or post-market surveillance. Class III devices require the most rigorous review, including clinical evidence of safety and effectiveness.
Your first step is to determine your device’s classification. The FDA maintains a product classification database you can search by device name or product code. If your device closely resembles something already on the market, the classification of that existing device will usually guide yours. If nothing like it exists, the classification process itself becomes part of your regulatory strategy.
The Three Main Regulatory Pathways
510(k) Premarket Notification
The 510(k) pathway is the most common route for Class II devices. It requires you to demonstrate that your device is “substantially equivalent” to a legally marketed device already on the market, known as a predicate. Substantial equivalence means your device has the same intended use and either the same technological characteristics (design, materials, energy source) or different characteristics that don’t raise new safety or effectiveness concerns.
Your submission must include a detailed comparison to the predicate device. If the devices differ in technology, you’ll need to provide performance data, both bench testing and potentially clinical testing, showing your device is at least as safe and effective as the predicate. The FDA’s review goal for 510(k) submissions received in 2025 is an average total time to decision of 112 calendar days. That clock includes time the FDA spends reviewing and time you spend responding to questions, so your actual experience may feel longer if the agency requests additional information.
The standard user fee for a 510(k) submission in fiscal year 2025 is $24,335. Small businesses pay $6,084, which is 25 percent of the standard fee. All 510(k) submissions must be filed electronically using the FDA’s eSTAR template through the CDRH Portal. This has been mandatory since October 1, 2023. If your eSTAR submission is incomplete or contains inaccurate responses, the FDA can place it on a 180-day hold until you submit a corrected version.
Premarket Approval (PMA)
PMA is the most demanding pathway and applies to Class III devices. Unlike the 510(k), which asks whether your device is similar enough to something already cleared, PMA requires you to independently prove that your device is safe and effective. This almost always means clinical trials.
A PMA application must include a complete device description, the results of all nonclinical (bench and animal) testing, and detailed clinical investigation data. The clinical section is extensive: you need to report protocols, subject selection criteria, demographics, safety and effectiveness outcomes, adverse reactions, device failures, and individual subject data for anyone who died during the study or dropped out. Statistical analyses of the trial results are required. The FDA also expects a discussion of contraindications and precautions.
The review timeline goal for PMA submissions received in 2025 through 2027 is an average of 285 calendar days from submission to decision. The standard user fee is $540,783, or $135,196 for qualifying small businesses. These fees cover only the FDA’s review. They don’t account for the cost of the clinical trials themselves, which can run into the millions depending on the device and study design.
De Novo Classification
The De Novo pathway exists for novel devices that are low-to-moderate risk but have no predicate on the market. If your device is genuinely new and doesn’t fit neatly into an existing classification, but also doesn’t carry the high risk that would require PMA, De Novo is likely your route.
You can submit a De Novo request in two ways. The first is after submitting a 510(k) and receiving a “not substantially equivalent” determination because no predicate exists. The second, and increasingly common approach, is to skip the 510(k) entirely and go straight to De Novo when you already know there’s no predicate to compare against.
A De Novo submission requires you to describe the device thoroughly, propose a classification (Class I or II), explain what controls would provide reasonable assurance of safety and effectiveness, and include supporting bench and clinical data where applicable. You also need to demonstrate that the device’s probable benefits outweigh its probable risks. The user fee is $162,235, or $40,559 for small businesses. De Novo submissions must use the eSTAR template as of October 1, 2025. One significant advantage: once your De Novo is granted, your device becomes a predicate that future manufacturers can reference in their own 510(k) submissions.
When You Need Clinical Trials
Clinical trials are not required for every device. Many 510(k) submissions clear the FDA with only bench testing data. But if your device poses a significant risk, has a new intended use, or lacks performance data from a substantially equivalent predicate, clinical evidence will likely be necessary.
The FDA regulates clinical trials for devices through the Investigational Device Exemption (IDE) process. The level of oversight depends on the risk category of your study. Significant risk device studies, which include implants, life-sustaining devices, and devices critical to diagnosing or treating disease, require both FDA approval and approval from an Institutional Review Board (IRB) at each study site before any patients are enrolled. You submit a formal IDE application, and the FDA has 30 calendar days to respond. If you don’t hear back within 30 days, the IDE is considered approved.
Nonsignificant risk device studies have a simpler path. You need only IRB approval at each participating institution. There’s no IDE application to the FDA. The distinction between significant and nonsignificant risk is critical to your timeline and budget, so getting that determination right early matters.
Use Pre-Submissions to Get Early Feedback
One of the most underused tools in the FDA’s regulatory process is the Q-Submission program, particularly the Pre-Submission (Pre-Sub) meeting. A Pre-Sub lets you present your regulatory strategy, testing plans, or clinical study design to the FDA before you file your actual submission. You receive written feedback and can request a meeting to discuss it.
Pre-Subs are available for 510(k), De Novo, PMA, and IDE submissions. They carry no user fee. The value is straightforward: you learn what the FDA expects before you invest heavily in testing that might not address the agency’s concerns. For novel devices or complex submissions, a Pre-Sub can save months of back-and-forth during the formal review.
Quality System Requirements
Before your device reaches the FDA’s review desk, you need a quality management system (QMS) in place. Any company that designs, manufactures, packages, labels, stores, installs, or services a finished device must establish and maintain a QMS that complies with 21 CFR Part 820, which now aligns with the international standard ISO 13485.
For Class II and Class III devices, this includes formal design controls. Design controls are a structured process for planning, reviewing, verifying, and validating your device’s design at every stage. They ensure the device you ultimately manufacture matches what you intended to build and what the FDA reviewed. If you’re developing a Class I device, design controls may not apply, but the broader quality system requirements still do.
Your QMS must also include a system for handling complaints and taking corrective and preventive action (CAPA). Every complaint involving a possible device failure needs to be documented, evaluated, and investigated. If the complaint triggers a mandatory report to the FDA under its adverse event reporting rules, your records need to capture what corrective action was taken. The FDA inspects manufacturing facilities, and a weak or missing quality system is one of the fastest ways to delay or derail your path to market.
Practical Cost and Timeline Summary
The total cost and time to market vary enormously by pathway. A straightforward 510(k) with only bench testing might cost $50,000 to $150,000 total (including the user fee, testing, and regulatory consulting) and reach clearance in four to six months. A PMA with a full clinical trial can take three to seven years from concept to approval and cost several million dollars or more, with the user fee alone exceeding half a million.
Here’s a quick comparison of the FDA user fees for fiscal year 2025:
- 510(k): $24,335 standard, $6,084 small business
- De Novo: $162,235 standard, $40,559 small business
- PMA: $540,783 standard, $135,196 small business
Small business fees are set at 25 percent of the standard fee. These are FDA review fees only. They don’t include the cost of testing, clinical trials, regulatory consultants, or building and maintaining your quality system. For startups, the difference between qualifying and not qualifying as a small business can meaningfully affect early-stage budgets.
The most important thing you can do early is correctly identify your device’s classification and regulatory pathway. Filing through the wrong pathway wastes time and money. Filing through the right pathway, with the right data package, after getting feedback through a Pre-Submission, is the most reliable way to avoid delays and reach the market efficiently.